S1A.



Lane	Description
1	mCherry Lysate
2	NiV-F AU1 Lysate
3	Affinity Purified NiV-F AU1 2 µg, 311Q154A
M	Dual Color MW Standard
4	NiV-G His6× Lysate
5	Affinity Purified NiV-G His6× 2 µg, 311Q140BC

Supplemental figure S1A. SDS-PAGE. NiV-F AU1 detected in lane 3 at approximately 60 kDa and 45 kDa. NiV-G His6× detected in lane 5 at 70 kDa. This photo was inverted to show purified NiV-F and NiV-G due to their low abundance. The overall yield of affinity purified NiVF-AU1 was 28 µg (35 mL 293T/17 cell lysate) and NiV-G His6× was 121 µg (7 mL 293T/17 cell lysate). Protein concentrations were estimated using absorbance at 280 nm.

S1B.



Lane	Description
M	Dual Color MW Standard
1	His-GRFT 200 ng 300P137A
2	Affinity Purified NiV-F AU1 250 ng, 311Q145A
3	Affinity Purified NiV-F AU1 200 ng, 311Q140A
4	mCherry Lysate 20 µg

Supplemental figure S1B. NiV-F AU1 Western blot probed with anti-AU1 antibody and LiCOR imaging identifies affinity purified AU1-tagged NiV-F protein (Lanes 2,3) at 60 kDa (uncleaved F_0) and 50 kDa (cleaved F_1). Affinity purified NiV-F batch 311Q140A and 145A were pooled and designated 311Q154A and quantitated using absorbance at 600 nm.

S1C.



Lane	Description
M	Dual Color MW Standard
1	Affinity Purified NiV-G His6× 1µg, 311Q140B

Supplemental figure S1C. NiV-G His6x Western blot probed with anti-His antibody and LiCOR imaging identifies His-tagged NiV-G at approximately 70 kDa.

S2A.





S2B.





S2C.





S2D.





Supplemental figure S2. GRFT (left column) and 3mG (right column) antiviral activity against human respiratory pathogens in Vero cells (A) rMVEZ-GFP(3), (B) hPIV3-GFP, (C) rMuV-GFP, and (D) hMPV-GFP. Total GFP fluorescence for rMV^{EZ}-GFP(3) and hPIV3-GFP infected cells treated with GRFT/3mG was normalized to untreated infected cells. A quantitative GFP cell counting assay was used to measure rMuV-GFP and hMPV-GFP infection. Objects ≥ 10 μm and that had raw fluorescence readings ≥ 5000 were counted as positive. Total numbers of GFP+ rMuV-GFP and hMPV-GFP infected cells treated with GRFT/3mG were normalized to untreated infected cells.

S3A.



S3B.



Supplemental figure S3. GRFT and 3mG have variable levels of antiviral activity against hemorrhagic fever viruses. Huh7 cells treated either with GRFT or 3mG were infected with recombinant reporter (A) Crimean-Congo Hemorrhagic Fever (rCCHFV-ZsG) and (B) Lassa Fever (rLASV-ZsG) viruses expressing ZsGreen protein for 72 h and measured for GFP fluorescence, which was normalized to that of respectively untreated infected cells.

S4A.



S4B.



S4C.



S4D.



Supplemental figure S4. Documentation of individual animal % weight changes and temperatures in (A) Q-GRFT treatment groups (green triangles), (B) 3mG treatment groups (blue squares), and (C) Virus control group (black circles). Shapes filled in red indicate euthanized animals for each respective treatment group. (D) Individual clinical scores for each study group. Increases in clinical scores correspond with increasing intensity of red color as indicated on the color scale. Gray shaded squares indicates deceased animal no longer being scored.